Key Summary
- NICE has recommended Fezolinetant (Veoza) to treat menopausal hot flushes and night sweats.
- It’s a non-hormonal, once-daily tablet, offering an option for women who cannot take HRT.
- Experts say it could help hundreds of thousands of women better manage menopause symptoms.
The National Institute for Health and Care Excellence (NICE) has recommended Fezolinetant, also known as Veoza, for women suffering from menopausal hot flushes and night sweats.
A non-hormonal treatment, Fezolinetant is suitable for women for whom hormone replacement therapy (HRT) is not feasible.
They can take Fezolinetant 45mg tablet once a day and it blocks the nerve pathways in the brain that trigger hot flushes and night sweats.
Fezolinetant can be used when HRT is medically not recommended, for example in cases of deep vein thrombosis or pulmonary embolism, or in some cases of diabetes or heart disease.
“The evidence shows Fezolinetant can meaningfully reduce symptoms, and was found to be cost effective, offering value for the taxpayer. This decision will give much-needed relief to those for whom HRT is unsuitable,” commented Helen Knight, director of medicines evaluation at NICE.
“It’s another vital treatment option which could help hundreds of thousands of women experiencing menopause to better manage their symptoms and feel more in control of their health,” said Dr Sue Mann, national clinical director in Women’s Health for NHS England.
